May 2003
Volume 44, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2003
Soluble Interleukin 2 Receptor (sIL-2R) Levels in Patients With Ocular Inflammation
Author Affiliations & Notes
  • T.G. Papadaki
    Massachusetts Eye and Ear Infirmary, Ocular Immunology and Uveitis Service, Boston, MA, United States
  • B. Iaccheri
    Massachusetts Eye and Ear Infirmary, Ocular Immunology and Uveitis Service, Boston, MA, United States
  • T. Fiore
    Massachusetts Eye and Ear Infirmary, Ocular Immunology and Uveitis Service, Boston, MA, United States
  • S. Androudi
    Massachusetts Eye and Ear Infirmary, Ocular Immunology and Uveitis Service, Boston, MA, United States
  • S. Thadani
    Massachusetts Eye and Ear Infirmary, Ocular Immunology and Uveitis Service, Boston, MA, United States
  • M. Meniconi
    Massachusetts Eye and Ear Infirmary, Ocular Immunology and Uveitis Service, Boston, MA, United States
  • W.G. Christen
    Department of Medecine, Division of Preventive Medecine, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, United States
  • C. Foster
    Department of Medecine, Division of Preventive Medecine, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, United States
  • Footnotes
    Commercial Relationships  T.G. Papadaki, None; B. Iaccheri, None; T. Fiore, None; S. Androudi, None; S. Thadani, None; M. Meniconi, None; W.G. Christen, None; C. Foster, None.
Investigative Ophthalmology & Visual Science May 2003, Vol.44, 4603. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      T.G. Papadaki, B. Iaccheri, T. Fiore, S. Androudi, S. Thadani, M. Meniconi, W.G. Christen, C. Foster; Soluble Interleukin 2 Receptor (sIL-2R) Levels in Patients With Ocular Inflammation . Invest. Ophthalmol. Vis. Sci. 2003;44(13):4603.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Abstract: : Purpose: To determine if raised sIL-2R levels in the serum of patients with uveitis are predictive of an associated systemic disease. Methods: We reviewed the clinical records of 234 patients examined at the Immunology and Uveitis Service of the Massachusetts Eye and Ear Infirmary between May 2001 to May 2002, for whom sIL-2R blood testing was requested. The result of the test, parameters from the ophthalmologic examination and discovery of an associated systemic disease were evaluated. Patients with associated systemic disease (Group 1) were compared to those without systemic disease (Group 2). Results: Group 1 was comprised of one hundred twenty one patients (51.7%) and Group two of 113 patients (48.3%). The mean sIL-2R value was 601.85 ± 507.23 and 619.94 ± 626.02 for Groups 1 and 2, respectively (p=0.81). The level of serum sIL-2R did not correlate with the level of ocular inflammation (r = - 0.03; p=0.63). When the value 820 was used as cut-off, the percentage of cases with normal versus high sIL-2R values was similar between both groups (p=0.96). Two other cut-off values were arbitrary chosen (600 and 400), but again no statistical differences were found (p >0.40). Conclusions: Serum sIL-2R levels are considered a marker of systemic immune system activation. However, in our series of patients with various forms of ocular inflammation, sIL-2R levels did not correlate with the degree of ocular inflammation nor the presence of systemic disease.

Keywords: inflammation • immunomodulation/immunoregulation • uveitis-clinical/animal model 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×